

RECEIVED
CENTRAL FAX CENTER

AUG 11 2006

Clark & Elbing LLP

101 Federal Street
Boston, MA 02110

Telephone 617-428-0200
Facsimile 617-428-7045
617-428-7046

OFFICIAL

Date: August 11, 2006

To: Examiner G.M. Shamcoo
U.S. Patent and Trademark Office
Group Art Unit 1626

Facsimile No.: 571-273-8300

From: Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Re: U.S. Patent Application Serial No. 10/802,902
SMALL MOLECULES USED TO INCREASE CELL DEATH
Yuan et al.
Filed March 16, 2004
Attorney Docket No. 00742/058004
Customer No. 21559
Confirmation No. 5299

Pages: 4, including cover page.

Message: The following papers are enclosed:

Interview Summary (3 pages)

NOTICE. This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

RECEIVED
CENTRAL FAX CENTER

AUG 11 2006

PATENT
ATTORNEY DOCKET NO. 00742/058004Certificate of Transmission by Facsimile: Date of Transmission: August 11, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to (571) 273-8300 on the date indicated above.

CLAIRE C. YORDS
Printed name of person transmitting facsimileC. Yords
Signature of person transmitting facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Yuan et al.	Confirmation No.:	5299
Serial No.:	10/802,902	Art Unit:	1626
Filed:	March 16, 2004	Examiner:	G. M. Shameem
Customer No.:	21559		
Title:	SMALL MOLECULES USED TO INCREASE CELL DEATH		

INTERVIEW SUMMARY

Applicants and the undersigned would like to thank Examiner Shamcem for the helpful telephonic interviews held on July 5, 2006 and July 19, 2006, in which proposed claim amendments were discussed. Specifically, in the July 5, 2006 interview, the Examiner noted that claims 1-9 would be allowable if the alkoxyl group was removed from position R₃; that claims 10-17 would be rejoined if the claims were limited to one or more specific cancers; and that claims 18-29 did not fall within the same restriction group as claims 1-17 and should be withdrawn or cancelled.

In the July 19, 2006 interview, applicants confirmed that the Examiner had received the Supplemental Information Disclosure Statement filed on July 18, 2006. In addition, applicants agreed to amend claims 1 and 7-9 to remove the alkoxyl group from


position R₃; to amend claim 10 to feature the recited cancers of claim 15; and to cancel claims 18-29. Applicants noted that the claim amendments were made solely to expedite prosecution and that applicants reserve the right to pursue any cancelled subject matter in this or a continuing application. In order to overcome the enablement rejection, the Examiner requested that applicants provide one or more references showing that the cancers of claim 10, as amended, are known to be associated with proteins containing a Bcl-2-homology-3 (BH3) domain. Applicants submitted the requested references and agreed-upon amendments in the Supplemental Reply filed July 19, 2006.

CONCLUSION

Applicants submit that the claims are in condition for allowance, and such action is respectfully requested. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: August 11, 2006



Kristina Bieker Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045